BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 312
- Registration Number
- NCT00720057
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT00717561
Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Bayer
- Registration Number
- NCT00713011
Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Bayer
- Registration Number
- NCT00710827
Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 402
- Registration Number
- NCT00709852
- Locations
- 🇮🇳
Piramal Diagnostic- Jankharia Imaging, Mumbai, Maharashtra, India
🇩🇪Universitätsklinikum Erlangen, Erlangen, Bayern, Germany
🇩🇪LMU Klinikum der Universität München - Großhadern, München, Bayern, Germany
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 921
- Registration Number
- NCT00699751
Mirena Efficiency and Tolerability During the First Year of Use
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 199
- Registration Number
- NCT00696202
Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 22
- Registration Number
- NCT00694850
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1114
- Registration Number
- NCT00692770
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Fast & Fed Pharmacokinetic (PK) Study
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00692016
© Copyright 2024. All Rights Reserved by MedPath